Liquidia Corporation (LQDA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Liquidia Corporation  (NASDAQ: LQDA)


Liquidia's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Liquidia's ROI in the second quarter of 2026?
Liquidia Corporation achieved a return on average invested assets (ROI) of 42.09 % in its second quarter of 2026 a new company high.

ROI has improved compared to 7.25% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 32 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 630 to 1196.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 50.26 % 55.03 % 39.12 % 38.05 % 59.83 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 333 391 324 270 246
Return On Investment (TTM) 42.09 % 7.25 % -26.03 % -52.73 % -68.2 %
LQDA's Overall Ranking # 1196 # 630 # 2500 # 2915 # 3207
Seq. Investment Change TTM 7.03 % 16.22 % 14.44 % 5.55 % 10.43 %
Seq. Net Income Change TTM 521.41 % - - - -
Net Income (TTM) in Millions 139 22 -69 -122 -149

LQDA Company Profile >> Back to LQDA Roi Comparisons >> See Annual LQDA Return On Investment



Return On Investment LQDA's Ranking
Within: No.
Industry # 18
Sector # 33
Overall # 1196

Return On Investment Statistics
High Average Low
42.09 %
-76.2 %
-457.94 %
(Jun 30 2026)   (Dec 31 2018)







Financial Statements
Liquidia's II. Quarter Investments $ 333 Millions LQDA's Balance sheet
Liquidia's II. Quarter Income $ 75 Millions Quarterly LQDA's Income Statement
LQDA's Income by Division See LQDA's Income by Division


LQDA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 192 189 100 117 82
Y / Y Investment Growth 1.93 % 88.94 % -14.64 % 42.87 % -0.86 %
Net Income in Millions -69 -130 -79 -41 -35
Y / Y Net Income Growth - - - - -
Annual Return On Investment -35.87 % -69.16 % -78.67 % -35.09 % -42.26 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LQDA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LQDA's Competitors
Subscribers only: Roi for Liquidia's Suppliers
Subscribers only: Return On Investment for LQDA's Customers

Other Ratios
LQDA's Roa LQDA's Inventory Turnover Ratio LQDA's Growth Rates LQDA's Dividend Statistics
LQDA's Profitability Ratios LQDA's Asset Turnover Ratio LQDA's Dividend Growth
LQDA's Roe LQDA's Valuation Ratios LQDA's Financial Strength Ratios LQDA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %

Date modified: 2026-09-26T07:39:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.